Ascent Industries (CSE:ASNT) is pleased to announce the formation of its Health and Medical Services division under its wholly-owned subsidiary AIC Health Services Corp. (“AIC Health”). AIC Health is developing as a new model for providing multidisciplinary, patient-centric, full-service health care to patients in Canada. AIC Health’s mandate is to develop a network of medical clinics accessible across Canada that provide general and specialized health care services using a variety of methods to treat patients, including pharmaceutical, homeopathic or natural medicines produced from the cannabis plant, combined with a plan for developing better health tailored to each patient as needed.

AIC Health’s first medical clinic and pharmacy is based in Winnipeg, Manitoba. Future expansion plans include acquiring or developing clinics across Canada, beginning in Calgary, Vancouver and Toronto. The medical clinics will be the first pillar of AIC Health’s model, with telehealth, medical and clinical research, and patient education expected to follow soon.


As part of this initiative, Ascent is pleased to welcome Matt Toews to the team as the Managing Director of AIC Health. Along side Matt, also joining Ascent is a team of healthcare and business professionals with extensive experience in a variety of sectors throughout the Canadian healthcare and pharmaceutical industry. Matt has twenty years of entrepreneurial experience, including owning and operating numerous medical clinics and pharmacies across Canada. Furthermore, he has developed several healthcare technology companies and brings a diverse background relating to finance, corporate structuring and technology. When asked about his vision for Ascent’s AIC Health division, Matt commented:

“I firmly believe that cannabis will play a significant role in our healthcare system going forward and we are excited to be able to join forces with Ascent’s established team of industry leading professionals to help execute our plan. With our mutual focus on the advancement of cannabis as part of a plan to treat patients holistically and provide access to information and resources for their benefit, we believe we are well positioned to provide high-quality health and medical services to patients across Canada for years to come.”

A large portion of the cannabis medical clinic market in Canada is currently focused on cannabis specific models that do not promote proper education, continuity of care, or patient retention. AIC Health’s model is to use multidisciplinary care that provides patients with a high touch experience to ensuring their treatment meets the goals of the medical therapy using a variety of treatments as best suited for patients.

Philip Campbell, CEO of Ascent, commented, “We have been working with patients and other medical stakeholders in Canada and the US for several years and we are excited to be able to launch this unique initiative into the Canadian medical services market. We look forward to growing the reach and service offering of AIC Health’s platform as we progress towards further acceptance and understanding of cannabis as a viable medical therapy, both domestically and abroad. Ascent is excited to align with Matt’s passion, vision and highly qualified team, which we believe will enable AIC Health to provide high quality relevant health services to patients particularly as related to medical cannabis therapies and education.”

About Ascent Industries Corp.

In Canada, Ascent (through its wholly-owned subsidiaries) is a Licenced Producer under the Access to Cannabis for Medical Purposes Regulations of Health Canada, with licences to cultivate cannabis and produce cannabis extracts. In addition, the Company is a Licenced Dealer under the Controlled Drugs and Substances Act (Canada), with the ability to produce, package, sell, send, transport and distribute medically focused cannabis products in Canada to other licenced entities and internationally in jurisdictions where medical cannabis is legal. In the United States, the Company holds licences in Oregon (for processing and for distribution of cannabis to any licenced entity in the state) and in Nevada (for cultivation and for production, processing and wholesale distribution of cannabis). In Europe, Agrima ApS, a Danish company and wholly-owned subsidiary of Ascent, has submitted licence applications for a Wholesaler Dealers Licence and Controlled Drug Licence in Denmark, and applications for the approval of eight products to the Danish Medical Cannabis Pilot Program.

The Company’s operations currently include licenced facilities in British Columbia, Canada, and in Oregon and Nevadain the United States. The Company is increasing its cultivation and production capacity from 50,000 square feet to 710,000 square feet in 2018, from which it expects to produce significantly higher amounts of cannabis and cannabis oil to support its expanding operations.

The Company offers a product suite of more than 40 unique products under several consumer-focused brands, including gel capsules, tinctures, medicinal oils, concentrates, vaporizer pens, pre-rolled joints, various edibles and raw flower. Through careful development of its sophisticated cannabis brands, Ascent is positioned to be a leader in branded, commercialized products in both medical and adult-use markets across North America and internationally.

In addition, the Company conducts cannabis-based research with Simon Fraser University and the University of Kentucky, including in the area of unique cannabinoid formulations that produce targeted physiological outcomes.

This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE has neither approved nor disapproved the contents of this press release.

NEITHER THE CSE OR ITS MARKET REGULATOR (AS THAT TERM IS DEFINED IN THE POLICIES OF THE CSE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the intention to acquire or develop clinics across Canada and the future plans for AIC Health. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Ascent assume no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Click here to connect with Ascent Industries (CSE:ASNT) for an Investor Presentation.

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”) , a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2021 . All financial information is provided in U.S. dollars unless otherwise indicated.

1Q 2021 Financial Highlights (Unaudited)

Keep reading... Show less

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Harvest Health & Recreation Inc. (“Harvest” or the “Company”) (OTC: HRVSF) in connection with the proposed acquisition of the Company by Trulieve Cannabis Corp. (“Trulieve”) (OTC: TCNNF). Under the terms of the merger agreement, Harvest shareholders will receive 0.1170 shares of Trulieve common stock for each Harvest share that they own, representing implied per-share merger consideration of approximately $4.79 based upon Trulieve’s May 7, 2021 closing price of $40.92 . Upon consummation of the transaction, current Harvest shareholders will own only 26.7% of the issued and outstanding pro forma Trulieve shares.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, will speak at Canaccord Genuity’s 5th Annual Global Cannabis Conference on Tuesday, May 11, 2021 at 2:30 p.m. EDT.

Participants may access a live webcast of the presentation by going to the Upcoming Events page at thecronosgroup.com . A replay will be made available shortly following the live presentation.

Keep reading... Show less

Numinus and Multidisciplinary Association for Psychedelic Studies collaboration
will conduct follow-on Compassionate Access trial in real-world setting in Vancouver, Canada

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today congratulates the Multidisciplinary Association for Psychedelic Studies (MAPS) and the MAPP1 trial study team for their announcement of results from the Phase 3 randomized clinical trial of MDMA-assisted therapy for the treatment of severe post-traumatic stress disorder (PTSD).

Keep reading... Show less

Combined Company Will Maintain Industry Leading Scale in Retail, Cultivation & Production

Footprint Provides National Scale with a Deep Regional Focus in Attractive Markets

Keep reading... Show less